AUR 112
Alternative Names: AUR-112Latest Information Update: 07 Feb 2024
At a glance
- Originator Aurigene Discovery Technologies
- Developer Aurigene Oncology
- Class Antineoplastics
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical B-cell lymphoma
Most Recent Events
- 15 Jan 2024 Aurigene plans a phase I trial for B-cell lymphoma (Aurigene Pipeline, January 2024)
- 11 Oct 2023 Preclinical trials in B-cell lymphoma in India (PO)
- 11 Oct 2023 Pharmacodynamics, pharmacokinetics and safety data from preclinical trials in B-cell lymphoma presented at the AACR-NCI-EORTC-2023 International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)